Administration of immune checkpoint blockers such as monoclonal antibodies to PD-1/PD-L1 or CTLA-4, have yielded significant clinical benefits in a subset of melanoma patients, eventually leading to eliminate all tumour cells through specific tumour immunity [1,2,3]. Here, CTLA4 is linked to neoplasm.